Literature DB >> 704036

Correlation of immune response with clinical stage in Lewis lung tumor-bearing mice.

T Kurata, M Micksche.   

Abstract

The effect of Lewis lung tumor growth in mice on the induction of primary immune response to SRBC, was investigated by PFC assay for measuring antibody activity and by footpad test as a correlate for delayed type hypersensitivity reactions. With the appearance of micrometastases in the lungs there was a decline in the humoral and cellular immune response to the SRBC. An increase of number and size of metastases in the lungs led to a further depression of the immune reactivity. Since the reduction of general immune response in mice bearing this tumor is not due to a direct influence of tumor cells, it might be assumed that suppressor cells or factors, are actively abrogating the general and also the tumor directed immune reactions.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 704036     DOI: 10.1159/000225275

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Effect of combined surgical and chemotherapeutic treatment of Lewis lung carcinoma.

Authors:  Z Szabó; O Dworák; L Kopper; K Lapis
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

2.  [Scalpel and CO2 laser in the animal experiment. A comparative study of inoculation tumors of the mouse].

Authors:  A Tuchmann; P L Fischer; P Bauer; H Plenk; O Braun; K Dinstl
Journal:  Langenbecks Arch Chir       Date:  1986

3.  Absence of generalized immunosuppression in C57BL/6J mice implanted with Lewis T241 fibrosarcoma or Lewis lung carcinoma.

Authors:  C E Jones; C T Lee; W Skinner; P Koyama; D Prescott
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

4.  Immunotherapy of Lewis lung carcinoma with hydrosoluble peptidoglycan monomer (PGM).

Authors:  G Sava; T Giraldi; J Tomasić; I Hrsak
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.